SRR12696766
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.600
- INTERFERON_GAMMA_RESPONSE+0.600
- COMPLEMENT+0.500
- FATTY_ACID_METABOLISM+0.500
- INFLAMMATORY_RESPONSE+0.500
- ADIPOGENESIS+0.400
- ALLOGRAFT_REJECTION+0.400
- APOPTOSIS+0.400
- CHOLESTEROL_HOMEOSTASIS+0.400
- IL6_JAK_STAT3_SIGNALING+0.400
Top 10 suppressed
- PANCREAS_BETA_CELLS-0.300
- E2F_TARGETS-0.200
- G2M_CHECKPOINT-0.200
- KRAS_SIGNALING_DN-0.200
- MITOTIC_SPINDLE-0.200
- MYC_TARGETS_V2-0.200
- SPERMATOGENESIS-0.200
- MYC_TARGETS_V1-0.100
- HEDGEHOG_SIGNALING+0.000
- MYOGENESIS+0.000
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
3 twins match this tumor's tissue · 7 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_VARR255N | pilocytic astrocytoma | — | 0.928 |
| 2 | BS_T0RKFEKR | pilocytic astrocytoma | — | 0.919 |
| 3 | BS_BKQZ550R | pilocytic astrocytoma | — | 0.914 |
| 4 | SRR934729 | — | — | 0.906 |
| 5 | BS_X16PENSA | pilocytic astrocytoma | — | 0.898 |
| 6 | BS_VW85Q4XJ | low-grade glioma | — | 0.897 |
| 7 | 3BCD8BE5-753D-43EF-B830-EA4356620A5C | — | — | 0.897 |
| 8 | BS_49852ZBH | pilocytic astrocytoma | — | 0.897 |
| 9 | BS_1SVVER1H | Schwannoma | — | 0.896 |
| 10 | SRR934945 | — | — | 0.894 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 38 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.600 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.600 | Idelalisib | — uncovered |
| COMPLEMENT | 0.500 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.500 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.500 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.400 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.400 | Idelalisib | — uncovered |
| APOPTOSIS | 0.400 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.400 | Remibrutinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.400 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.400 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.400 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.400 | Remibrutinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.400 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.300 | Inavolisib | — uncovered |
| COAGULATION | 0.300 | Binimetinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.300 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.300 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.300 | Temsirolimus | — uncovered |
| IL2_STAT5_SIGNALING | 0.300 | Idelalisib | — uncovered |